Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target
Key Highlights
- ➤Noble initiates Cosmos Health (COSM) coverage with Outperform rating and $1.40 price target
- ➤$1.40 target implies approximately 493% upside from $0.236 closing price
- ➤Noble forecasts 2026 revenue of $90.0 million, rising to $131.2 million in 2027
- ➤Adjusted EBITDA forecast turns positive at $3.9 million in 2026, reaching $27.4 million in 2028
- ➤Gross margin forecast expands from 12.1% in 2025 to 31.5% in 2028
Expert Statements
Greg Siokas, CEO of Cosmos Health
“We are delighted to welcome Noble's coverage of Cosmos Health. For years, we have been building a vertically integrated healthcare platform, and today that platform is entering its most exciting phase, with growth coming from our proprietary brands, our expanding manufacturing operations and our rapidly scaling U.S. subscription business.”
Greg Siokas, CEO of Cosmos Health
“Coverage from a firm with Noble's track record helps a much broader investor audience discover the transformation underway at Cosmos Health. We are energized by the opportunity ahead, and we are determined to keep executing and delivering results that create lasting value for our shareholders.”
CHICAGO, IL / ACCESS Newswire / October 28, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Noble Capital Markets ("Noble") has initiated company-sponsored equity research coverage on the Company with an Outperform rating and a price target of $1.40 per share. The research report, authored by Noble Capital Markets Senior Research Analyst Michael Kupinski, is available on Channelchek, along with the latest news, market data, and additional information on Cosmos Health (COSM).
Management encourages investors to review the report and visit Channelchek for ongoing coverage and updates.
Get started
Create a free account to read the full story.